New 'Sandwich' strategy aims to stop leukemia relapse after CAR-T therapy
NCT ID NCT06985498
First seen Mar 28, 2026 · Last updated Jun 19, 2026 · Updated 8 times
Summary
This study tests a new treatment plan for young adults and adults with B-cell acute lymphoblastic leukemia. The approach uses a combination of immunotherapies before and after a stem cell transplant, including a 'sandwich' of two types of CAR-T cells. The goal is to reduce the risk of the cancer coming back. The trial is currently suspended and aims to enroll 40 participants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBKASTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
The First Affiliated Hospital of Soochow University
Suzhou, China
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CD22/CD19 CAR-T cells, CD19-directed T-cell engager, and inotuzumab ozogamicin
What this could lead to
If it works, this could offer a way to lower the chance of leukemia coming back after CAR-T therapy, potentially improving long-term survival.
What could go wrong
This is a small, early-phase trial (40 people) that is currently suspended. The approach is complex and may cause serious side effects, and it's too soon to know if it will work better than existing treatments.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.